TRC Plus for Hemophilia
Make hemophilia more predictable and affordable
Hemophilia is a genetic, incurable bleeding disorder affecting 30,000 males in the United States1. The care journey for and costs associated with hemophilia are often unpredictable, complex, and expensive for plans and patients. Individualized treatment plans can include clotting factor injections, monoclonal antibodies, or even gene therapies.
Total cost and care for hemophilia
100%
in-market factor therapy and gene therapy access through Accredo, ensuring continuity of patient care2
$1.8M
aggregate savings driven through proprietary hemophilia-specific TRC waste management protocols3
Total cost and care for hemophilia
100%
in-market factor therapy and gene therapy access through Accredo, ensuring continuity of patient care2
$1.8M
aggregate savings driven through proprietary hemophilia-specific TRC waste management protocols3
Hemophilia designed support
Realize plan savings and drive a better patient experience with capabilities such as:
A self-service dashboard
to review therapy utilizations and gene therapy forecasting that projects potential impact to plan.
Therapy discounts across all hemophilia treatment options
including gene therapies at cost, and an average annual savings of $200K on non-gene therapies.3
A comprehensive care model
with dedicated TRC specialists, in-home and virtual care options, and multi-level waste reduction through our Blood Disorder TRC.
Navigation assistance
to guide patients through coverage policies and utilization management requirements for gene therapies.
Sources
- Institute for Clinical and Economic Review, Sept. 2022
- Accredo BoB blended factor discount averages for 2022, based on 500k life client and payers who were not previously enrolled in exclusive Accredo arrangements. While these factor figures are average, actual patient spend can vary widely.
- Journal of Managed Care & Specialty Pharmacy: Vol 29, No 1, Jan, 2023. “Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste”.